• Aucun résultat trouvé

Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed

N/A
N/A
Protected

Academic year: 2021

Partager "Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed"

Copied!
2
0
0

Texte intégral

(1)

HAL Id: pasteur-02010612

https://hal-riip.archives-ouvertes.fr/pasteur-02010612

Submitted on 7 Feb 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of sci- entific research documents, whether they are pub- lished or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License

Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed

Josef Finsterer, Sinda Zarrouk-Mahjoub

To cite this version:

Josef Finsterer, Sinda Zarrouk-Mahjoub. Costs for mitochondrial medicine will remain high as long

as mitochondrial disorders are misdiagnosed. Molecular Genetics and Metabolism Reports, Elsevier,

2017, 13, pp.41. �10.1016/j.ymgmr.2017.08.002�. �pasteur-02010612�

(2)

Contents lists available at ScienceDirect

Molecular Genetics and Metabolism Reports

journal homepage: www.elsevier.com/locate/ymgmr

Correspondence

Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed

A R T I C L E I N F O

Keywords:

Mitochondrial Multiorgan Epidemiology Costs

Respiratory chain

Letter to the Editor

We read with interest the article by McCormack et al. about frequency and costs of hospitalisations of mitochondrial disorder (MID) patients in California [1]. There are several reasons why the fi gures provided are underestimations.

First, quite a number of MIDs go undetected or are misinterpreted as another disease. Particularly, patients with multiorgan disease are fre- quently in fact mitochondrial multiorgan disorder syndromes (MIMODSs) [2]. As soon as the cause of multisystem disease remains obscure, a MID should be suspected and considered as a differential diagnosis. Since work-up of suspected MID is time-consuming, logistically demanding, cost- intensive, and often associated with inconclusive or negative results, it is frequently not initiated at all, why many of these patients go undetected for years or forever.

Second, ICD codes do not cover the entire spectrum of MIDs. For example, MIRAS, LBSL, or PCH may be missed. Even ICD10 does not cover all speci fi c and nonspeci fi c MIMODS.

Third, coding of diagnoses is often insufficiently effectuated. Sometimes, only major diagnoses are encoded. Sometimes no ICD codes are al- located at all.

Fourth, a number of congenital MIDs may remain undiagnosed because patients decease during the fi rst few days or months of life. During this short period it is often impossible to complete a comprehensive diagnostic work-up. Often these patients do not undergo autopsy.

Fifth, MIDs are often insufficiently diagnosed. According to various classification criteria, MIDs may be diagnosed as possible, probable, or de fi nite [3]. Often MIDs are only diagnosed upon histochemical or biochemical investigations, without the inclusion of functional or genetic studies.

Accordingly, we do not agree with the fi gure 1:4300 for the prevalence of MIDs [1]. Nonspeci fi c MIDs are regarded much more frequent occurring with a prevalence of 1:400 [4].

Overall, the costs in mitochondrial medicine will remain high if patients are misdiagnosed and thus mistreated. The longer a misdiagnosis is maintained, the more costs incur.

References

[1] S.E. McCormack, R. Xiao, T.J. Kilbaugh, M. Karlsson, R.D. Ganetzky, Z.Z. Cunningham, A. Goldstein, M.J. Falk, S.M. Damrauer, Hospitalizations for mitochondrial disease across the lifespan in the U.S. Mol. Genet. Metab. 121 (2017) 119–126.

[2] J. Finsterer, A. Bastovansky, Multiorgan disorder syndrome (MODS) in an octagenarian suggests mitochondrial disorder, Rev. Med. Chil. 143 (2015) 1210–1214.

[3] F.P. Bernier, A. Boneh, X. Dennett, C.W. Chow, M.A. Cleary, D.R. Thorburn, Diagnostic criteria for respiratory chain disorders in adults and children, Neurology 59 (2002) 1406–1411.

[4] J. Poulton, J. Finsterer, P. Yu-Wai-Man, Genetic counselling for maternally inherited mitochondrial disorders, Mol. Diagn. Ther. 21 (2017) 419–429.

Josef Finsterer Krankenanstalt Rudolfstiftung, Vienna, Austria Sinda Zarrouk-Mahjoub University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia E-mail address: fifigs1@yahoo.de

http://dx.doi.org/10.1016/j.ymgmr.2017.08.002 Received 1 August 2017; Accepted 1 August 2017

There are no conflicts of interest.

☆☆

Both authors contributed equally.

No funding was received.

★★

Author contribution: JF: design, literature search, discussion, first draft, SZ-M: literature search, discussion, critical comments.

Corresponding author at: Postfach 20, 1180 Vienna, Austria.

Molecular Genetics and Metabolism Reports 13 (2017) 41

Available online 07 August 2017

2214-4269/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

MARK

Références

Documents relatifs

mitochondries sont impliquées dans la SLA, mais aussi dans plusieurs maladies neurodégénératives comme l'Alzheimer ou le parkinson, voire dans de nombreux cancers. •

In particular, (1) mitochondria are major sources of ATP and building blocks for the proliferation of malignant cells; (2) progressing cancer cells display an increased threshold

Among them: (i) both groups of disorders are caused by the partial or total loss of function of a single protein or enzyme essential to the mitochondrial RC or to the FAO pathway;

Both indices are consistent with an hourly time step and are calculated to express thermal comfort or heat stress for the body as a whole in a homogeneous indoor environment during

Did the de- scribed patient develop hematological manifestations either as a manifestation of the genotype or as a side of clozapine, which may induce leucopenia and

Dry biomarkers for MIDs include the history and clinical neurological exam and structural and functional imaging studies of the brain, muscle, or myocardium by ultrasound,

For example, miR-29b has been involved in the etiology of prostate cancer [7], miR-34a promotes cell cycle arrest and apoptosis and suppresses cell adhesion in osteosarcoma

This study shows that adult MIDs manifest as MIMODS in the vast majority of the cases; that organs most frequently affected in MIMODS are the muscle, CNS, endocrine glands,